WO2023109979A3 - 一种展示新冠s蛋白的融合蛋白和重组病毒粒子及其应用 - Google Patents

一种展示新冠s蛋白的融合蛋白和重组病毒粒子及其应用 Download PDF

Info

Publication number
WO2023109979A3
WO2023109979A3 PCT/CN2023/076443 CN2023076443W WO2023109979A3 WO 2023109979 A3 WO2023109979 A3 WO 2023109979A3 CN 2023076443 W CN2023076443 W CN 2023076443W WO 2023109979 A3 WO2023109979 A3 WO 2023109979A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
cov
sars
fusion protein
fusion
Prior art date
Application number
PCT/CN2023/076443
Other languages
English (en)
French (fr)
Other versions
WO2023109979A2 (zh
Inventor
陈瑞婷
孙慧敏
毛水花
周孟云
宋家升
Original Assignee
浙江迪福润丝生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 浙江迪福润丝生物科技有限公司 filed Critical 浙江迪福润丝生物科技有限公司
Publication of WO2023109979A2 publication Critical patent/WO2023109979A2/zh
Publication of WO2023109979A3 publication Critical patent/WO2023109979A3/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

提供了一种展示新冠S蛋白的融合蛋白和重组病毒粒子及其应用，属于生物制品技术领域。提供了一种表达新冠S蛋白的融合基因及融合蛋白，该融合基因或融合蛋白包含新冠S蛋白的胞外结构域序列与禽副黏病毒科F蛋白的跨膜结构域和胞内结构域序列。同时，含有该序列的重组NDV病毒具有较强的中和抗体的能力。可见，S蛋白的胞外域编码序列和APMV病毒科病毒(除NDV外)F蛋白的跨膜结构域和胞内结构域编码序列相融合所产生的融合基因或蛋白，具有成为优秀新冠疫苗候选抗原的巨大潜力。
PCT/CN2023/076443 2021-12-16 2023-02-16 一种展示新冠s蛋白的融合蛋白和重组病毒粒子及其应用 WO2023109979A2 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111541851.3A CN114213547A (zh) 2021-12-16 2021-12-16 一种展示新冠s蛋白的融合蛋白和重组病毒粒子及其应用
CN202111541851.3 2021-12-16

Publications (2)

Publication Number Publication Date
WO2023109979A2 WO2023109979A2 (zh) 2023-06-22
WO2023109979A3 true WO2023109979A3 (zh) 2023-08-03

Family

ID=80703140

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/076443 WO2023109979A2 (zh) 2021-12-16 2023-02-16 一种展示新冠s蛋白的融合蛋白和重组病毒粒子及其应用

Country Status (2)

Country Link
CN (2) CN114213547A (zh)
WO (1) WO2023109979A2 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114213547A (zh) * 2021-12-16 2022-03-22 浙江迪福润丝生物科技有限公司 一种展示新冠s蛋白的融合蛋白和重组病毒粒子及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021206581A1 (en) * 2020-04-05 2021-10-14 Dukhovlinov Ilya Vladimirovich Genetic construct-based vaccine against coronavirus infection
WO2021226348A2 (en) * 2020-05-07 2021-11-11 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease virus expressing sars-cov-2 spike protein and uses thereof
US11179459B1 (en) * 2021-01-28 2021-11-23 Libentech Co., Ltd. Vaccine composition for preventing human infection of SARS coronavirus and alleviating infection symptoms
CN114213547A (zh) * 2021-12-16 2022-03-22 浙江迪福润丝生物科技有限公司 一种展示新冠s蛋白的融合蛋白和重组病毒粒子及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113480618B (zh) * 2020-10-16 2024-06-21 浙江大学 表达新冠病毒蛋白的重组麻疹病毒及其应用
CN113293145B (zh) * 2021-02-01 2022-08-26 上海青赛生物科技有限公司 一种麻疹病毒活载体新冠疫苗

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021206581A1 (en) * 2020-04-05 2021-10-14 Dukhovlinov Ilya Vladimirovich Genetic construct-based vaccine against coronavirus infection
WO2021226348A2 (en) * 2020-05-07 2021-11-11 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease virus expressing sars-cov-2 spike protein and uses thereof
US11179459B1 (en) * 2021-01-28 2021-11-23 Libentech Co., Ltd. Vaccine composition for preventing human infection of SARS coronavirus and alleviating infection symptoms
CN114213547A (zh) * 2021-12-16 2022-03-22 浙江迪福润丝生物科技有限公司 一种展示新冠s蛋白的融合蛋白和重组病毒粒子及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SUN WEINA, SUN WEINA, LEIST SARAH, MCCROSKERY STEPHEN, LIU YONGHONG, SLAMANIG STEFAN, OLIVA JUSTINE, AMANAT FATIMA, SCHÄFER ALEXAN: "Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate", EBIOMEDICINE, ELSEVIER BV, NL, vol. 62, 1 December 2020 (2020-12-01), NL , pages 103132, XP055872539, ISSN: 2352-3964, DOI: 10.1016/j.ebiom.2020.103132 *
YANG, YUYING; ZUO, DAIYING: "Progress on the Research of Novel Coronavirus Vaccine", JOURNAL OF SHENYANG PHARMACEUTICAL, vol. 38, no. 7, 31 July 2021 (2021-07-31), LIAONING, CN , pages 762 - 769, XP009548115, ISSN: 1006-2858, DOI: 10.14066/j.cnki.cn21-1349/r.2021.0143 *

Also Published As

Publication number Publication date
CN117247463A (zh) 2023-12-19
WO2023109979A2 (zh) 2023-06-22
CN114213547A (zh) 2022-03-22

Similar Documents

Publication Publication Date Title
Hai et al. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes
Zhang et al. Current advancements and potential strategies in the development of MERS-CoV vaccines
Steel et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain
Margine et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses
CL2019001000A1 (es) Proteínas de fusión fc heterodiméricas il15/il15ralfa
AU2019283892A1 (en) Anti-human papillomavirus 16 E7 T cell receptors
Ellebedy et al. Re-engaging cross-reactive memory B cells: the influenza puzzle
ES2561081T3 (es) Anticuerpo que contiene IgG2 que presenta una mutación de aminoácido introducida en el mismo
EA201000077A1 (ru) Вирус гриппа с нарушенной репликацией для экспрессии гетерологичных последовательностей
Rameix-Welti et al. Avian Influenza A virus polymerase association with nucleoprotein, but not polymerase assembly, is impaired in human cells during the course of infection
Goris et al. Differential sensitivity of differentiated epithelial cells to respiratory viruses reveals different viral strategies of host infection
Ader et al. Mechanism for active membrane fusion triggering by morbillivirus attachment protein
Chen et al. Influenza A viruses expressing intra-or intergroup chimeric hemagglutinins
PE20211291A1 (es) Anticuerpos anti-ox40 y metodos de uso
MX2020005127A (es) Plataforma de presentacion en endosporas basadas en paenibacillus, productos y metodos relacionados.
WO2023109979A3 (zh) 一种展示新冠s蛋白的融合蛋白和重组病毒粒子及其应用
Han et al. Fine epitope mapping of monoclonal antibodies against hemagglutinin of a highly pathogenic H5N1 influenza virus using yeast surface display
AU2018249796A1 (en) Antibody Fc variants for improving blood half-life
Sánchez-San Martín et al. Cross-inhibition of chikungunya virus fusion and infection by alphavirus E1 domain III proteins
Gao et al. Expression and functional identification of recombinant SARS-CoV-2 receptor binding domain (RBD) from E. coli system
SV2017005545A (es) Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y metodos para usar los mismos
MX2021001163A (es) Péptidos multimerizantes derivados del dominio de pliegue kelly roll del capsómero pentagonal de adenovirus.
MX2020001058A (es) Marcadores de fusión para expresión de proteínas recombinantes.
WO2018069947A8 (en) Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
Fischer et al. Expression, characterisation and antigenicity of a truncated Hendra virus attachment protein expressed in the protozoan host Leishmania tarentolae

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE